Aimmune Therapeutics (AIMT) Earns Outperform Rating from Wedbush

Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research report issued to clients and investors on Monday.

A number of other equities research analysts have also weighed in on the company. Credit Suisse Group lifted their price objective on Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Roth Capital lifted their price objective on Aimmune Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. BidaskClub upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 8th. Finally, Robert W. Baird started coverage on Aimmune Therapeutics in a research report on Wednesday, December 20th. They issued an “outperform” rating and a $64.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $57.25.

Aimmune Therapeutics (NASDAQ AIMT) opened at $37.84 on Monday. Aimmune Therapeutics has a 1 year low of $15.97 and a 1 year high of $40.65. The stock has a market capitalization of $1,975.03, a P/E ratio of -16.10 and a beta of -0.82.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.09. equities analysts forecast that Aimmune Therapeutics will post -2.51 EPS for the current year.

In other news, insider Douglas T. Sheehy sold 1,648 shares of Aimmune Therapeutics stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $37.33, for a total value of $61,519.84. Following the sale, the insider now directly owns 1,648 shares in the company, valued at approximately $61,519.84. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Susan E. Barrowcliffe sold 75,000 shares of Aimmune Therapeutics stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $37.14, for a total value of $2,785,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 134,294 shares of company stock worth $5,097,144. Corporate insiders own 17.59% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AIMT. Carillon Tower Advisers Inc. bought a new stake in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $58,838,000. Alliancebernstein L.P. boosted its position in shares of Aimmune Therapeutics by 109.5% during the fourth quarter. Alliancebernstein L.P. now owns 1,400,281 shares of the biotechnology company’s stock valued at $52,959,000 after purchasing an additional 731,927 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of Aimmune Therapeutics by 3,092.5% during the third quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock valued at $13,873,000 after purchasing an additional 542,111 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Aimmune Therapeutics by 12.6% during the second quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock valued at $50,923,000 after purchasing an additional 276,978 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Aimmune Therapeutics by 26.6% during the second quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock valued at $22,351,000 after purchasing an additional 228,429 shares in the last quarter. Institutional investors own 73.14% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/14/aimmune-therapeutics-aimt-earns-outperform-rating-from-wedbush.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply